TY - JOUR
T1 - Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease
T2 - Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein
AU - Davidson, Michael H.
AU - Abate, Nicola
AU - Ballantyne, Christie M.
AU - Catapano, Alberico L.
AU - Xu, Xia
AU - Lin, Jianxin
AU - Rosenberg, Elizabeth
AU - Tershakovec, Andrew M.
PY - 2008/12
Y1 - 2008/12
N2 - Background: Recent evidence suggests that in addition to low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo-B), non-high-density lipoprotein cholesterol (non-HDL-C), some lipoprotein ratios, and C-reactive protein (CRP) are predictive of coronary heart disease (CHD) risk. This post-hoc analysis of two trials comparing single-tablet ezetimibe/simvastatin (EZE/SIMVA) to atorvastatin (ATORVA) or rosuvastatin (ROSUVA) evaluates the proportion of patients attaining LDL-C
AB - Background: Recent evidence suggests that in addition to low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo-B), non-high-density lipoprotein cholesterol (non-HDL-C), some lipoprotein ratios, and C-reactive protein (CRP) are predictive of coronary heart disease (CHD) risk. This post-hoc analysis of two trials comparing single-tablet ezetimibe/simvastatin (EZE/SIMVA) to atorvastatin (ATORVA) or rosuvastatin (ROSUVA) evaluates the proportion of patients attaining LDL-C
KW - Atorvastatin
KW - Coronary heart disease: Ezetimibe
KW - Hypercholesterolemia
KW - Rosuvastatin
KW - Simvastatin
UR - http://www.scopus.com/inward/record.url?scp=57349163065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57349163065&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2008.10.003
DO - 10.1016/j.jacl.2008.10.003
M3 - Article
C2 - 21291777
AN - SCOPUS:57349163065
VL - 2
SP - 436
EP - 446
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
SN - 1933-2874
IS - 6
ER -